Penserra Capital Management LLC Immuno Gen, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$4.75 - $7.5 $21,992 - $34,725	-4,630 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $401 - $527	80 Added 1.76%	4,630 $26,000
Q2 2021 Aug 12, 2021	BUY	$5.79 - $8.6 $781 - $1,161	135 Added 3.06%	4,550 $29,000
Q1 2021 May 13, 2021	BUY	$6.5 - $10.53 $292 - $473	45 Added 1.03%	4,415 $35,000
Q4 2020 Feb 12, 2021	BUY	$3.7 - $7.66 $10,656 - $22,060	2,880 Added 193.29%	4,370 $28,000
Q3 2020 Nov 13, 2020	BUY	$3.45 - $4.89 $5,140 - $7,286	1,490 New	1,490 $5,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.